亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI

医学 经皮冠状动脉介入治疗 心肌梗塞 临床终点 传统PCI 心脏病学 内科学 安慰剂 再灌注治疗 再灌注损伤 麻醉 缺血 随机对照试验 病理 替代医学
作者
David Adlam,Maciej Zarębiński,Neal Uren,Paweł Ptaszyński,Keith G. Oldroyd,Shahzad Munir,Azfar Zaman,Hussain Contractor,Róbert Gábor Kiss,István Édes,Joanna Szachniewicz,Gergely Nagy,Mario J. García,János Tomcsányi,John Irving,Andrew Sharp,Piotr Musiałek,Géza Lupkovics,Cheerag Shirodaria,Joseph B. Selvanayagam
出处
期刊:International Journal of Cardiology [Elsevier BV]
卷期号:347: 1-7 被引量:16
标识
DOI:10.1016/j.ijcard.2021.11.016
摘要

Background Ischemia-reperfusion injury remains a major clinical problem in patients with ST-elevation myocardial infarction (STEMI), leading to myocardial damage despite early reperfusion by primary percutaneous coronary intervention (PPCI). There are no effective therapies to limit ischemia-reperfusion injury, which is caused by multiple pathways activated by rapid tissue reoxygenation and the generation of reactive oxygen species (ROS). FDY-5301 contains sodium iodide, a ubiquitous inorganic halide and elemental reducing agent that can act as a catalytic anti-peroxidant. We tested the feasibility, safety and potential utility of FDY-5301 as a treatment to limit ischemia-reperfusion injury, in patients with first-time STEMI undergoing emergency PPCI. Methods STEMI patients (n = 120, median 62 years) presenting within 12 h of chest pain onset were randomized at 20 PPCI centers, in a double blind Phase 2 clinical trial, to receive FDY-5301 (0.5, 1.0 or 2.0 mg/kg) or placebo prior to reperfusion, to evaluate the feasibility endpoints. Participants underwent continuous ECG monitoring for 14 days after PPCI to address pre-specified cardiac arrhythmia safety end points and cardiac magnetic resonance imaging (MRI) at 72 h and at 3 months to assess exploratory efficacy end points. Results Intravenous FDY-5301 was delivered before re-opening of the infarct-related artery in 97% participants and increased plasma iodide levels ~1000-fold within 2 min. There was no significant increase in the primary safety end point of incidence of cardiac arrhythmias of concern. MRI at 3 months revealed median final infarct sizes in placebo vs. 2.0 mg/kg FDY-5301-treated patients of 14.9% vs. 8.5%, and LV ejection fractions of 53.9% vs. 63.2%, respectively, although the study was not powered to detect statistical significance. In patients receiving FDY-5301, there was a significant reduction in the levels of MPO, MMP2 and NTproBNP after PPCI, but no reduction with placebo. Conclusions Intravenous FDY-5301, delivered immediately prior to PPCI in acute STEMI, is feasible, safe, and shows potential efficacy. A larger trial is justified to test the effects of FDY-5301 on acute ischemia-reperfusion injury and clinical outcomes. Clinical Trial Registration: CT.gov NCT03470441; EudraCT 2017-000047-41
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
简单柏柳完成签到,获得积分10
6秒前
6秒前
20秒前
20秒前
26秒前
星辰大海的应助被现实的如之采纳,获得10
34秒前
风中的晓兰完成签到,获得积分10
40秒前
温暖的岂愈完成签到,获得积分10
41秒前
善良的觅荷完成签到,获得积分10
1分钟前
LL完成签到 ,获得积分10
1分钟前
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
秋风的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
jb4652完成签到,获得积分10
1分钟前
1分钟前
无限寒珊完成签到,获得积分10
1分钟前
落润晓发布了新的文献求助10
1分钟前
欣喜的凡霜完成签到,获得积分10
1分钟前
Rick完成签到,获得积分10
2分钟前
tszjw168完成签到 ,获得积分10
2分钟前
拼搏淇完成签到,获得积分10
2分钟前
Lucas的应助被taka采纳,获得10
2分钟前
执着忆寒完成签到,获得积分10
2分钟前
嘻嘻哈哈的应助被活力棉花糖采纳,获得10
2分钟前
2分钟前
taka发布了新的文献求助10
2分钟前
科研通AI6.4的应助被晚星采纳,获得10
2分钟前
3分钟前
Rick发布了新的文献求助10
3分钟前
踏实的白卉完成签到,获得积分10
3分钟前
跳跃的冰安完成签到,获得积分10
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
3分钟前
3分钟前
3分钟前
晚星发布了新的文献求助10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158751
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719285
捐赠科研通 7748357
什么是DOI,文献DOI怎么找? 3427080
关于科研通互助平台的介绍 2551971
邀请新用户注册赠送积分活动 2471339